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Purpose: To evaluate the effect of formulation variables on the bioadhesion and release properties of 
bioadhesive cyproheptadine hydrochloride tablets. 
Methods: Screening of polymers - hydroxypropyl methylcellulose, (HPMC), sodium carboxy methyl 
cellulose (CMC), and Carbopol 974p and 934p - in solution form were carried out by shear stress and 
detachment force measurement,based on Taguchi model, in order to determine their bioadhesion 
properties. Central composite design (CCD) was applied to optimize the combined effects of the 





detachment force of a sustained release tablet formulation of cyproheptadine hydrochloride containing 
also a prompt dose of the drug.  
Results: The shear stress of 3 % solution of HPMC was greater than that of an equivalent concentration 
of Carbopol 934P. The values of K, n, R
2 
and detachment force for the optimized formulation (F0) were 
0.269, 0.696, 0.964 and 0.066 Newton (N), respectively, and showed good correlation with the predicted 
values, thus confirming the practicability and validity of the model.  
Conclusion: Gastric retention time can be increased for cyproheptadine hydrochloride by formulating it 
as a bioadhesive tablet that enhances the retention of the dosage form in the stomach and hence 
gastric absorption of the drug.  
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INTRODUCTION 
 
Oral ingestion is the most convenient and 
commonly used route of drug administration. 
More than 50 % of drug delivery systems 
available in the market are oral drug delivery 
systems. These systems have the obvious 
advantages of ease of administration and 
patient acceptance [1,2].  
 
Bioadhesion is an adhesive interaction 
between an oral pharmaceutical system and 
biological surface. It has been suggested that 
delay in gastrointestinal (GI) transit, brought 
about by intimate and extended contact 
between bioadhesive system and 
mucus/mucosal lining, will improve drug 
bioavailability and duration of action. Though 
the oral route is the most commonly 
employed route of drug administration, it is 
not suitable for drugs which are susceptible 
to gut and/or hepatic metabolism as well as 
drugs which cause gastrointestinal side 
effects [3].  
 
Mucous membranes are the moist surfaces 
lining the walls of various body cavities. They 
consist of a connective tissue upper layer 
(epithelial layer), the surface of which is 
made moist usually by the presence of 
mucus. The major components of all mucus 
gels are mucin glycoprotein. Mucin 
glycoproteins are the most important 
structure-forming component of the mucus 
gel, resulting in its characteristic gel-like, 
cohesive and adhesive properties. It is as 
thick as 1mm in humans [4]. 
 
Although various selective antihistaminic 
drugs are available in the market, their 
delivery systems may cause various hazards 
and patient inconvenience. Conventional 
dosage forms of these drugs, such as tablets, 
capsules, lotions, suspensions and syrups, 
often fail to achieve effective management of 
these diseases due to peak level-associated 
disadvantages such as drowsiness, dry 
mouth, confusion and weight gain. In spite of 
their anti-allergic properties, they may 
produce allergic manifestations and also 
cause patient inconvenience [5]. 
Gastro-retentive dosage forms remain in the 
stomach for several hours due to their 
modified gastric retention time (GRT). 
Prolongation of GRT may sustain drug 
release behavior and provide a better 
alternative for maintenance of systemic drug 
concentration within the therapeutic window 
[6-9] 
 
Cyproheptadine hydrochloride is well 
absorbed after oral administration. It has a 
short half life of 3 h and hence require 
frequent administration to maintain optimum 
plasma concentration which cause patients’ 
non-compliance. These characteristics make 
it a good candidate for the formulation of an 
extended-release dosage form to minimize 
patients non-compliance and maximum 







Cyproheptadine Hydrochloride (Indian 
Pharmacopoeia, IP) was procured from 
Mederich Pharmaceuticals, Bangalore, India. 
Hydroxypropyl methylcellulose (HPMC), 
Carbomer (Carbopol) 974P, and sodium 
carboxymethylcellulose (CMC) were obtained 
from Apotex Research Pvt Ltd, Bangalore, 
India. Carbomer (Carbopol) 934p (Strides 
Acrolabs, Bangalore, India) and 
microcrystalline cellulose (MCC) (Maple 
Biotech Pvt Ltd, Pune, India) were also used. 
All other chemicals and reagents used were 
of analytical grade. 
 
Shear stress measurement 
 
Screening of the various polymers - HPMC, 
CMC, and Carbopol 974p and 934p - was 
carried out by shear stress measurement. 
[12,13]. Two smooth, polished glass slides 
were selected, one of which was fixed with an 
adhesive onto a fixed surface.  The second 
(upper) slide was tied with a thread, which 
was then passed over a pulley and tied to a 
pan. The weight of the pan and frictional 
force of the upper slide was nullified by 
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putting a weight on the pan such that the 
upper slide moves freely after infinitesimal small 
increase of weight in the pan. One drop of each 
polymer (3 % aqueous solution) was placed at 
the center of the fixed slide and then a second 
slide was pressed down with a weight (100g) for 
fixed intervals of 5, 10, 15 and 30 min, after 
which weights were added to the pan. The /load 
required to pull the upper slide or cause it to 
slide down from the fixed slide represents the 
adhesion strength. Taguchi design was applied 
for further screening of the polymers for use in 
tablet formulations based on the measurement 
of the detachment force. 
 
Following this screening, the best two 
bioadhesive polymers, HPMC and Carbopol 
934P, were selected for the formulation of 
tablets. Various ratios of these two polymers, 
with respect to the weight of the drug, were then 
optimized by Central composite design (CCD). 
 
Formulation of Cyproheptadine tablets  
 
The cyproheptadine hydrochloride (HCl) tablets 
prepared consisted of a sustained release dose 
as the tablet core, and an outer prompt dose 
component. The sustained release core was 
prepared by wet granulation method and 
optimized by CCD. An accurately weighed 
quantity of cyproheptadine HCl and polymer 
were blended together. The ingredients were 
mixed in geometric proportion, after first 
grinding separately in a mortar with a pestle, to 
form a homogenous mixture. The powder 
mixture was granulated with sufficient ethanol to 
make a damp mass. The damp mass was then 
passed through a 1 mm sieve and dried in an 
oven at 40 0C for 30 min. The granules were 
then successively passed through sieves with 
aperture  size of 250 and 90 µm, respectively.  
 
The resulting granules were mixed with 
magnesium stearate, talc and remaining 
quantity of MCC, and compressed in a tablet 
machine, using 8 mm flat punches, to make the 
core tablets. 
Various concentrations of polymers, based on 
the Taguchi design (Table 1), were screened for 
detachment force in core tablet formulations. 
Selection of the polymers, using the Taguci OA 
design, was based on maximum detachment 
force. 
 
The best two polymers obtained from the 
Taguchi OA design were subjected to CCD, 
as in Table 2, using different ratio of HPMC  
 
Table 1: Composition of various tablet core formulations based on Taguchi Orthogonal Array (OA) Design 
 
Ingredient HPMC Carbapol 934P Carbopol 974P CMC Lactose 
A1 15 - - - 101 
A2 30 - - - 86 
A3 45 - - - 71 
A4 - 7.5 - - 108.5 
A5 - 15 - - 101 
A6 - 22.5 - - 93.5 
A7 - - 7.5 - 108.5 
A8 - - 15 - 101 
A9 - - 22.5 - 93.5 
A10 - - - 60 56 
A11 - - - 75 41 
A12 - - - 9 26 
Composition is given in terms of mg per tablet. Each formulation contained 11, 4, 4 and 15 mg of cyproheptadine 
hydrochloride, magnesium stearate, talc and microcrystalline cellulose (MCC), respectively; CMC = sodium 
carboxymethyl cellulose 
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and Carbopol 934p with respect to the weight 
of the drug at an α (star point or distance 
from the centre calculated by the formula 2
2/4
) 
value of 1.414 with three centre point to 
formulate bioadhesive core tablets. The 
resultant core formulations were evaluated 
for detachment force, dissolution (n value, 
which characterizes release mechanism of 
the drug, with n ≤ 0.45 corresponding to 
Fickian diffusion mechanism; 0.45 < n < 0.89 
to non-Fickian diffusion; n = 0.89 to case II 
transport; and n > 0.89 to supercase II 
transport), as well as for release rate 
constant (K), variability of % drug release 
(R
2
) in a given concentration of the polymer, 
assay, and % drug release, as response 
variables. These response variables were 
subjected to multiple regression analysis and 
ANOVA to find out the relation between the 
independent variables and response. The 
final formula, F0, was then prepared by 
optimization based on the release rate and 
detachment force of the formulations 
obtained by CCD. Around this final 
formulation, the loading (prompt) dose 
(consisting of drug along with 
superdisintegrant, cross carmellose sodium) 
was directly compressed to completely 
surround the core tablet core using 10 mm 
concave punches.  
 
 
Table 2: Application of Central composite design (CCD) to optimize polymer combination for 
the formulation of optimized bioadhesive core tablets  
 
Ingredient F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 
HPMC 20 20 10 30 5.86 20 34.14 30 10 20 20 
Carbopol 934P 3.96 7.5 5 10 7.5 11 7.5 5 10 7.5 7.5 
Lactose 92 88.5 101 76 102.6 85 74.36 81 96 88.5 88.5 
 
Composition is given as mg per tablet. Each formulation contained 11, 4, 4 and 15 mg of cyproheptadine hydrochloride, 
talc, magnesium stearate and microcrystalline cellulose (MCC ), respectively; HPMC = hydroxypropyl methylcellulose 
 
Measurement of detachment force of 
tablets 
 
This test was carried out using the tablet core 
(i.e., the sustained release dose component) 
to measure in-vitro bioadhesive capacity of 
the bioadhesive polymers to the mucosa of 
rat stomach. The animals were sacrificed by 
cervical dislocation. The stomach mucosa 
was collected and stored in a deep freezer at 
-21 
0
C. During the experiment, Tyrode 
solution was added to the vial, the brim of 
which was tied with rat mucosa and the other 
end was fixed to a glass mortar on a hot plate 
maintained at 37 
0
C. The adhesion force of 
the tablets was then measured (n = 6) as 
follows. A hole was drilled in centre of  the 
tablet to be tested. One end of the thread 
was passed through it and tied and the other 
end was passed through the pulley and tied 
to a pan on which a beaker was placed. The  
weight of the pan was nullified by suspending 
the weight. Water was added to the beaker 
using a burette. The tablet was allowed to 
stay in contact with the tissue for 30 min. 
Water was then added to the beaker from a 
burette. The quantity of water required to 
separate the tablet from the tissue surface 
was noted and this value was converted to 
detachment force (in newtons) using Eq 1.13.  
 
Detachment force = (0.00981 x w)/2 ……..(1) 
where w is the mean weight of the added 
water.  
 
Optimization procedure  
 
Taguchi design was applied to reduce the 
number of experiments to optimize the range 
of variable concentrations needed to obtain 
maximum bioadhesion. The same optimized 
levels of the variable (polymer concentration) 
were used for further optimization of core 
tablets by central composite design. 
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Statistical experimental design of two factors 
at three different levels was used to evaluate 
the influence and interactions of the three 
levels to the final responses tested. Such 
three level-CCD requires a minimum number 
of tests for each variable. The fact that the 
expected responses do not vary in a linear 
manner with the selected variable and to 
enable the quantification of the prediction of 
the responses, a central composite plan was 
selected, where the response could be 
modeled in a quadratic manner since the 
error in predicting the response increases 
with the distance from the centre of the 
modeled region. It is advisable to limit the use 
of the models to an area bound by values 
corresponding to –α to +α limits. 
 
The parameters were carefully selected to 
carry out composite factorial design (one of 
the forms of CCD where the effect of each 
factor is evaluated at five different levels) 
based on codified values of –α, -1 , 0 +1, +α. 
The value of alpha is chosen such that the 
variance of the response predicted by the 
model would depend only on the distance 
form the centre of the modeled region. The 
value of alpha was taken here as 1.414. 
Three replicate central point were prepared to 
estimate the degree of experimental error for 
the modeled responses. 
 
Four key responses as mentioned earlier in 
the text were selected to derive the 
mathermatical models for evaluating relevant 
factors. The experimental levels of the 
variables (maximum and minimum) boundary 
of each response variables are defined in the 
optimization techniques. The quadratic model 
test for the CCD is as shown in Eq 2. 
 






where Y= response, x1 = drug: polymer ratio, 
x2 = polymer : polymer ratio, b0 is the 
intercept for the regression line, x1x2 is the 
interaction and other b’s stands = for 
coefficients. 
 
In vitro dissolution studies 
 
Drug release studies on the tablets were 
performed using a United States 
Pharmacopoeia dissolution rate test 
apparatus (type 1, 100 rpm, 37 
0
C) in 900 ml 
simulated gastric fluid (0.1M HCl) without 
enzymes. A 5 ml aliquot was withdrawn at 
different time intervals, filtered through 0.45 µ 
filter and the dissolution medium replenished 
with 5 ml of fresh dissolution fluid. The drug 
content of the sample was determined by 
Elico UV-Visible Spectrophotometer (model 
SL-159) at 290 nm after suitable dilution of 





To analyze the mechanism of drug release 
and release rate kinetics from the dosage 
form, the responses obtained from 
formulations F1 to F11 and F0 were 
subjected to zero order, first order, 
Korsmeyer and Peppas release models using 
Prism
®
 and Sigma plot
®
 software, for curve 
fitting and statistical data analysis, 
respectively. Finally all the response, viz, n, 
K, R
2
, %Assay, %drug release and time of 
maximum drug release were fitted to the 
quadratic regression model as shown in Eq 2 
to determine the coefficients and intercept for 
the factors tested at each response. The 
optimum formulation was constructed using 
this regression line and to predict the 
responses form the response boundary, 
ANOVA was performed to ascertain statistical 





The shear stress of the four polymer tested is 
depicted in Fig 1. As the time of contact with 
mucus is increased the shear force of the 
polymers also increased almost linearly 
except for Carbopol 974p which initially 
showed a rapid increase of shear stress and 
thereafter a steady state or plateau was 
observed.  
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Fig 1: Screening of polymers by shear stress 
assessment  
      = HPMC; □ =  Carbopol 934P; ∆ = Sodium CMC; ♦ = 
Carbopol 974P 
 
Drug dissolution and release kinetics  
 
In vitro parameters for the various tablet 
formulations are listed in Table 3. Drug 
release throughout the study period ranged 
from 80 to 98 % while diffusion coefficient (n) 
ranged from 0.3 to 0.7, K from 0.3 to 0.5 and 
R
2
 from 0.8 to 0.9. The curve-fitting results for 
drug release from the formulations gave an 
insight into the release rate and release 
mechanism [8].  
 
The final optimized composition of the core 
tablet (sustain release dose component), F0, 
is as follows: cyproheptadine HCl 11 mg, 
HPMC 28 mg, Carbopol 934p 4.65 mg, 
magnesium stearate 4 mg, talc 4 mg, MCC 
15 mg, and lactose 82.97 mg. The 
composition of the loading (prompt) dose, 
which was coated around the core tablet, is: 
cyproheptadine HCl 4 mg, MCC 30 mg, 
lactose 184 mg, magnesium strearate 10 mg, 





The bioadhesive cyproheptadine HCl tablet 
formulation was designed to increase 
bioavailability and prolong therapeutic action. 
The bioadhesive nature and controlling 
characteristics of certain polymers can be 
attributed to shear stress, detachment force 
and release.[13] 
 











Time for drug 
release (h) K n R
2 
F1 0.0228 89.32 91.41 11 0.3217 0.412 0.9826 
F2 0.0299 92.75 97.14 10 0.3902 0.401 0.980 
F3 0.011 92.37 98.56 5 0.510 0.342 0.887 
F4 0.0214 90.79 89.65 13 0.3406 0.335 0.928 
F5 0.0548 88.22 94.59 7 0.4286 0.375 0.965 
F6 0.0166 94.08 97.89 10 0.365 0.423 0.984 
F7 0.0263 94.70 81.96 12 0.3008 0.4 0.980 
F8 0.0276 95.67 91.24 12 0.363 0.372 0.968 
F9 0.0251 95.31 96.84 9 0.3756 0.4 0.979 
F10 0.0246 90.79 91.22 10 0.2749 0.496 0.950 
F11 0.0584 98.00 93.91 9 0.4029 0.403 0.962 
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Shear stress  
 
The highest shear stress was shown by 3 % 
solutions of HPMC and Carbopol 934P. This 
may be attributed to the swelling of the 
polymers which leads to greater 
entanglement of polymeric chains due to 
controlled hydration. Thus, shear stress 
increases with time as a result of the 
controlled rate of hydration. On the other 
hand, CMC and Carbopol 974p showed 
uncontrolled hydration and swelling with time 
which resulted in less increase in shear 
stress. 
 
Detachment force  
 
Tablet cores containing either HPMC or 
Carbopol 934p showed higher detachment 
force than the other two polymers, leading to 
the exclusion of the latter from further 
studies. The combination of HPMC and 
Carbopol 934p exhibited higher rate of 
swelling, higher chain entanglement and 
higher friction than the individual polymers; 
thus, the polymer combination yielded a 
higher detachment force. The exact ratio of 
the polymer combination that exhibited the 
highest bioadhesive strength was obtained by 





Formulation F11 (HPMC:Carbopol 934p in 
the ratio 20:7.5) showed the highest drug 
content (98 %) due probably to uniform 
mixing of the polymers and the drug. 
However, uniformity in mixing can be also 
achieved for the other formulations if the 
formulation conditions are appropriately 
modified. 
 
Kinetic release mechanism (curve fitting) 
 
Based on the dissolution profile, the drug 
release data were best fitted to the 
Korsmeyer - Peppas model for all the 
formulations as they showed high correlation 
coefficient (R
2
 = 0.98) Thus, drug release 
occurred via non-Fickian diffusion. The 
response dependant variables - K, n, R
2
 and 
detachment force - were examined by 
subjecting these responses to multiple 
regression analysis of variance, and the 
following observations were made. 
 
Effect of formulation variables on release 
kinetics (K) 
 
The model term, K, for cyproheptadine 
hydrochloride release was significant (p = 
0.0478), indicating adequate fit to the surface 
linear model. In this model, as the 
concentration of HPMC increased, K value 
also increased, and this may be attributed to 
the swelling of the polymers which in turn 
increased the influx of water leading to 
increased drug diffusion. Carbopol 934p 
similarly caused an increase in the value of 
K.  
 
Effect of formulation variables on diffusion 
coefficient (n) 
 
The model term for n was highly significant (F 
= 12.98), indicating adequate fit to the 
quadratic model. At low concentrations of 
HPMC, n decreased while at higher 
concentrations, n increased; similarly, with 
increase in Carbopol 934p concentration n 
also increased. Thus, the optimum 
concentration of this two-polymer 
combination exhibited the desired 
predetermined controlled release and 
bioadhesive property.  
 
Effect of formulation variables on detachment 
force  
 
Detachment force was not important for the 
design chosen. As HPMC increased, 
detachment force also increased while for 
Carbopol 934P, detachment force first 
increased and then decreased. However, the 
optimized mixture of these two polymers in 
the tablet core showed sustained increase in 
detachment force over time. This is probably 
due to the fact that the rate-limiting hydration  
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 Detachment force 
Actual Predicted Actual Predicted Actual Predicted Actual Predicte
d 
0.1269 0.1283 0.696 0.7 0.964 0.845 0.066 0.06 
 
interaction of Carbopol 934p was controlled 
by HPMC. 
 
Effect of formulation variables on R
2  
 
The model term for R
2 
was significant (F = 
1.1572), indicating adequate fit to the 
quadratic model. As HPMC concentration 
increased, R
2 
also increased; a  similar 




A numerical optimization technique by the 
desirability approach was used to generate 
the optimum setting for the formulation using 
maximum adhesive force as well as favorable 
drug release time, K, n and R
2
. When this 
was done, F0 showed drug release for up to 
16 h. The optimized formulation was 
prepared using the various criteria mentioned 
earlier and the formulation was evaluated for 
various responses. The optimization results 
obtained are shown in Table 4. 
The results showed a good relationship 
between the experimental and predicted 
values, which confirms the practicability and 
validity of the model. Furthermore, it can be 
stated that the mechanism of drug release 
from the bioadhesive drug delivery system 




The final optimized cyproheptadine 
hydrochloride formulation, incorporating 
Carbopol 934p and HPMC, resulted in tablets 
with superior bioadhesion and prolonged 
release. It consisted of a sustained release 
tablet core around which was compressed a 
prompt release coat containing sodium 
carboxymethyl cellulose that would 
disintegrate within 5 min to provide 
immediate therapeutic effect. Furthermore, 
the application of optimization technique is a 
useful tool, particularly in evaluating several 
response variables as the observed variables 
were in close agreement with predicted 
values for the optimized formulation, thus 
demonstrating the feasibility of the 
optimization procedure used. Consequently, 
formulation of a bioadhesive tablet of 
cyproheptadine hydrochloride using 
optimization technique has been successfully  
 
achieved and the approach used holds 
promise for other drugs that have an 
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